Platelets News and Research

RSS

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

29 Jul 2014

First systematic analysis indicates that about 1 in 3000 donors in England have HEV

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around 1200 HEV-containing blood components (eg, red cells, platelets, and fresh frozen plasma) are likely to be transfused every year in England.

29 Jul 2014

Scientists develop next-generation platelet bioreactor to generate functional human platelets

Scientists at Brigham and Women's Hospital (BWH) have developed a scalable, next-generation platelet bioreactor to generate fully functional human platelets in vitro. The work is a major biomedical advancement that will help address blood transfusion needs worldwide.

22 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Mitek Sports Medicine expands early intervention options for sports medicine physicians and patients

Mitek Sports Medicine, a leader in orthopaedics sports medicine and a part of the DePuy Synthes Companies of Johnson & Johnson, announced the launch of MONOVISC High Molecular Weight Hyaluronan, a single-injection treatment for knee pain related to osteoarthritis and the PEAK Platelet Rich Plasma (PRP) System, a new device that produces high quality PRP in only 2.5 minutes.

14 Jul 2014

Cerus enters into $30M growth capital credit facility with Oxford Finance

Cerus Corporation announced today that it has entered into a $30 million growth capital credit facility with Oxford Finance LLC.

1 Jul 2014

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV).

4 Jun 2014

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes.

3 Jun 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

On Friday, April 18th PGFX Patent Holdings, operating as Heritage Biosciences, LLC made an asset acquisition of proprietary methods, devices and intellectual property from Orogen Biosciences, Inc.

31 May 2014

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center.

28 May 2014

Recycling patients' red blood cells during heart surgery better than banked blood transfusion

Patients whose own red blood cells are recycled and given back to them during heart surgery have healthier blood cells better able to carry oxygen where it is most needed compared to those who get transfusions of blood stored in a blood bank, according to results of a small study at Johns Hopkins.

9 May 2014

Researchers demonstrate possibility of using blood test to detect depression

Researchers at the MedUni Vienna have demonstrated the possibility of using a blood test to detect depression. While blood tests for mental illnesses have until recently been regarded as impossible, a recent study clearly indicates that, in principle, depression can in fact be diagnosed in this way and this could become reality in the not too distant future.

30 Apr 2014

Platelets News and Research

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

First systematic analysis indicates that about 1 in 3000 donors in England have HEV

Scientists develop next-generation platelet bioreactor to generate functional human platelets

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Mitek Sports Medicine expands early intervention options for sports medicine physicians and patients

Cerus enters into $30M growth capital credit facility with Oxford Finance

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Recycling patients' red blood cells during heart surgery better than banked blood transfusion

Researchers demonstrate possibility of using blood test to detect depression

Cerus, Nipro partner to develop key component of INTERCEPT red cell disposable set

Study: Mutations could have major impact on treatment of human blood diseases

Cook Medical launches Stemulate Pooled Human Platelet Lysate cell culture media supplement

Study shows how infection worsens damage caused by stroke

Researcher develops synthetic hydrogel that promotes natural clotting, heals surgical wounds

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms